Therapeutic Focus Target opportunities in oncology and neurological disorders where RNA modulation and spliceosome interactions offer a differentiating mechanism, aligning with Rgenta’s RNA-targeting small molecules and proprietary platform.

Lead Programs Prioritize partnering or licensing discussions around RGT-61159 and RGT-0474060, given their progression in oncology and Huntington's disease respectively, with emphasis on preclinical/early clinical data milestones and potential co-development options.

Clinical Momentum Leverage recent ASCO and AACR-related updates and data presentations to time outreach around upcoming data readouts, expansion opportunities, or strategic collaborations with pharma companies seeking novel RNA-targeting modalities.

Financial Readiness Engage potential investors or pharma sponsors noting a robust financing history (Series A rounds totaling over $100M and a current funding base) to support joint development, translational research, or milestone-based collaborations.

Infrastructure Fit Propose collaboration that leverages Rgenta’s data-driven target discovery and existing tech stack (cloud, collaboration and project management tools) to accelerate research partnerships, CRO/CMC alignment, and scalable development programs.